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Behorende bij het proefschrift 
 
Tetrahydrobiopterin in Phenylketonuria. Who can benefit? 
 
1. The BH4 loading test (in non-neonates) should last for at least 48 rather than 24 hours as late 
responders are worth detecting and should be allowed to be tested for true responsiveness. (this 
thesis) 
2. Patients carrying two null-mutations in the phenylalanine hydroxylase gene are no 
candidates for BH4 treatment. (this thesis) 
3. BH4 responsiveness can be predicted in a BH4 loading test with a baseline phenylalanine 
concentration < 400 µmol/l when the test is positive, otherwise a retest with phenylalanine 
loading can be considered. (this thesis) 
4. Defining BH4 responsiveness is not clear-cut and should take into account that some patients 
already have a relatively high protein intake and thereby a ≥ 100% increase in natural protein 
tolerance is not recommended (this thesis) 
5. An 8 hour or even 24 hour neonatal BH4 loading test can miss long-term BH4 responsive 
patients. As a delay in treatment should be avoided, an 24 hour neonatal BH4 loading test should 
be the maximum length or otherwise the BH4 withdrawal test should be considered. (this thesis) 
6. BH4 treatment appears to be safe (in non-pregnant PKU patients), adverse events are likely to 
disappear with reduced therapeutic BH4 doses. (this thesis) 
7. BH4 treatment is associated with lower prolactin concentrations, suggesting higher dopamine 
availability, independent of a decrease in phenylalanine concentration in male PKU patients. (this 
thesis) 
8. Under current conditions BH4 treatment does not affect brain neurotransmitter concentrations 
in PKU mice, but it does seem to increase brain serotonin concentrations in wild type mice. (this 
thesis) 
9. “Treat the patient and the phenotype, not the genome” (Charles Scriver) 
10. “Chronisch ziek zijn vraagt om chronisch optimisme” (Loesje.nl) 
11. “Change favors the prepared mind” (Pasteur) 
12. “Alleen ga je sneller, maar samen kom je verder” (Afrikaans spreekwoord) 
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